Eli Lilly announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its... Read More
Please join with us to fuel the next wave of progress.
Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.
Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.
